Excellent outcome of young adults with aggressive non-Hodgkin lymphomas treated with CHOP-like regimens

Leukemia. 2014 Nov;28(11):2260-3. doi: 10.1038/leu.2014.213. Epub 2014 Jul 9.

Authors

K Hohloch¹, S Zeynalova², G Held³, M Ziepert², M Loeffler², G Wulf¹, N Schmitz⁴, M Pfreundschuh³, L Trümper¹

Affiliations

¹ Department of Hematology and Medical Oncology, Georg August University, Goettingen, Germany.
² Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
³ Department of Internal Medicine I, University of Saarland, Saar, Germany.
⁴ Department of Hematology and Stem Cell Transplantation, St Georg Asklepios Hospital, Hamburg, Germany.

PMID: 25005242
DOI: 10.1038/leu.2014.213

No abstract available

Publication types

Letter
Meta-Analysis

MeSH terms

Adolescent
Adult
Antibodies, Monoclonal, Murine-Derived / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cyclophosphamide / therapeutic use
Doxorubicin / therapeutic use
Female
Humans
Lymphoma, Non-Hodgkin / drug therapy*
Lymphoma, Non-Hodgkin / mortality*
Male
Prednisone / therapeutic use
Proportional Hazards Models
Rituximab
Treatment Outcome
Vincristine / therapeutic use
Young Adult

Substances

Antibodies, Monoclonal, Murine-Derived
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
Prednisone

Supplementary concepts

CHOP protocol